|
EP3105208A1
|
|
Process for the preparation of enzalutamide
|
|
US2015112085A1
|
|
Pure crystalline Form II of L-malic acid salt of sunitinib and processes for its preparation
|
|
US2015329526A1
|
|
Process for the preparation of pazopanib or salts thereof
|
|
US2014065191A1
|
|
Topical pharmaceutical composition comprising nanonized silver sulfadiazine
|
|
AU2012354150A1
|
|
Amorphous vilazodone hydrochloride, a process for its preparation and pharmaceutical compositions thereof
|
|
US2014271846A1
|
|
Gastroretentive dosage system and process of preparation thereof
|
|
BR112014000935A2
|
|
stable solid oral dosage form and malaria treatment method
|
|
AU2012277403A1
|
|
Novel salts of sitagliptin
|
|
AU2011306398A1
|
|
Matrix metalloproteinase inhibitors
|
|
AU2011211338A1
|
|
Substituted pyrrole derivatives and their use as HMG-CO inhibitors
|
|
AU2011284341A1
|
|
N-Methylformamide solvate of dasatinib
|
|
AU2011222462A1
|
|
Polymorph of 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methylthiazole-5-carboxylic acid
|
|
AU2011210327A1
|
|
Crystalline forms of L-malic acid salt of sunitinib
|
|
AU2011210326A1
|
|
Sorafenib dimethyl sulphoxide solvate
|
|
AU2010308021A1
|
|
Extended release pharmaceutical compositions of paliperidone and processes of preparation thereof
|
|
AU2010299484A1
|
|
Polymorphs of sorafenib acid addition salts
|
|
BRPI1010969A2
|
|
processor for preparing and purifying olmesartan medoxomila and olmesartan medoxomila
|
|
AU2006242824A1
|
|
Antimicrobial agents
|
|
AU2006201553A1
|
|
Orally administered controlled delivery system for once daily administration of ciprofloxacin
|
|
AU2004218178A1
|
|
3,3-diarylpropylamine derivatives and processes for isolation thereof
|
